Erasca, INC 10-Q quarterly reports

Erasca, Inc. reported its first quarter 2026 financial results, highlighted by a significant in-process R&D expense related to a license expansion, while also disclosing a new intellectual property dispute with Revolution Medicines.

Erasca, Inc. reports reduced net losses and extended cash runway into the second half of 2028, driven by strategic reprioritization and pipeline advancements.

Erasca, Inc. reported reduced net losses and extended its cash runway into the second half of 2028, while strategically reprioritizing its oncology pipeline.

Erasca, a clinical-stage oncology company, announces its Q1 2025 financial results and a strategic shift to prioritize its RAS-targeting programs.

Erasca Inc. reported its third quarter 2024 financial results, highlighting a strategic reprioritization and advancements in its clinical programs.

Erasca Inc. announced its second quarter 2024 financial results, highlighting a strategic shift to focus on its naporafenib program and two new RAS-targeting programs.

Erasca, a clinical-stage oncology company, reported a net loss of $35.0 million for the first quarter of 2024, while highlighting progress in its clinical programs and securing additional funding.